top of page
CGTI.png

Gwendolyn Binder PhD

President, Science and Technology at Cabaletta Bio

Dr. Binder was one of Cabaletta’s first employees, joining in February 2019, and was most recently Executive Vice President of Science and Technology. At Cabaletta, she established and currently leads the preclinical, translational, manufacturing and quality teams. In addition to her position at Cabaletta, she serves on the Board of Directors of Instil Bio, Inc., a company developing tumor infiltrating lymphocytes for cancer immunotherapy, and as a member of the Scientific Advisory Board for Immatics N.V., which is developing engineered T cell immunotherapy for cancer. Prior to joining Cabaletta, Dr. Binder was the Chief Technology Officer of Adaptimmune Therapeutics plc, where she led the research team after establishing the U.S. arm of the company and building the early manufacturing, quality and translational research teams, including providing oversight on the build out of a commercial scale cell therapy manufacturing facility. Earlier in her career, Dr. Binder served as Director of Operations for the Translational Research Program at the University of Pennsylvania, where she progressed multiple Investigational New Drug application (“IND”) submissions for novel engineered T cell therapies in human immunodeficiency virus (“HIV”) and oncology, including the CD19 CAR IND acquired by Novartis (now Kymriah®), the first human gene editing IND, and three TCR engineered T cell therapy studies in oncology and HIV. Prior to that, she served as the Director of Scientific Affairs at VIRxSYS Corporation in Gaithersburg, Maryland where she supported the development of the first clinical lentiviral vector used in humans, for the application of engineered T cell therapy for HIV. Dr. Binder studied viral immunology and translational research at the Johns Hopkins University in Baltimore, Maryland where she earned a Ph.D. in Cellular and Molecular Medicine. She has authored over 30 publications in the field, including top international journals such as Science and Nature Medicine. She is a recognized leader in the biotechnology sector for the translational and clinical advancement of novel T cell therapies for patients with serious diseases.

Share
  • LinkedIn
  • Youtube
  • X
  • Instagram
How we drive innovation
STORIES
MEETINGS
MEMBERS
Speakers

Uwe Gottschalk

Uwe Gottschalk is Chief Scientific Officer (CSO) at Lonza since July 2017. Between 2014 and 2017 he served as a Chief Technology Officer where he established and led the global Research and Technology organisation of Lonza Pharma/Biotech.

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Jesse McCool

CSO of Bionova Scientific

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Thomas Potgieter

SVP of Global Cell Therapy Development & Operations at Bristol Myers Squibb

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Angela Vollstedt, PhD MBA

Director Global Cell & Gene Therapies Portfolio Management at Novartis

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Paolo Martini

Chief Research & Development Officer at ReAlta Life Sciences former CSO at Moderna

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS

Warner Biddle

CEO at Kyverna Therapeutics former interim CEO at Kite a Gilead Company

Jens H. Vogel, SVP & Global Head of Biotech at Bayer is an advisor of GBX EVENTS
bottom of page